Breadcrumb

[A12-14] Axitinib - Benefit assessment according to § 35a Social Code Book V (dossier assessment)

Overview

Overview

Commission: Commission awarded on 2012-10-01 by the Federal Joint Committee (G-BA)
Status:Commission completed
Department/Division:Drug Assessment
Current document:PDF Extract of dossier assessment  [PDF, 318 kB]Further documents
Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Contact address:to the contact form
Linked projects: [A17-12] Axitinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)
Status: Commission completed


Report documents

Report documents

PublishedDocumentSizeType 
2013-01-02 Extract of dossier assessment 318 kBPDFdownload file
2013-01-02 Dossier assessment (German version) 629 kBPDFdownload file

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.


At a glance

Accompanying information

Extract of dossier assessment

  File-Icon  Axitinib - Benefit assessment according to § 35a Social Code Book V (dossier assessment) [PDF, 318 kB]

Federal Joint Committee (G-BA)

2013-03-21 A G-BA decision was published.

G-BA documents on this decision (German only)

Press releases

2013-01-02 Axitinib for kidney cancer: hint of considerable added benefit



Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close